MDT-AP-3156
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 3.7
- sex
- M
- new_clusters
- C1
- umap1_2d
- 3.701855442
- umap2_2d
- 0.649220307
- umap1_3d
- 0.010033577
- umap2_3d
- -2.717504901
- umap3_3d
- -0.88867488
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
- ANGIOGENESIS+0.530
- INTERFERON_ALPHA_RESPONSE+0.520
- INFLAMMATORY_RESPONSE+0.510
- INTERFERON_GAMMA_RESPONSE+0.510
- TNFA_SIGNALING_VIA_NFKB+0.500
- IL6_JAK_STAT3_SIGNALING+0.470
- ALLOGRAFT_REJECTION+0.450
- KRAS_SIGNALING_UP+0.420
- TGF_BETA_SIGNALING+0.420
Top 10 suppressed
- DNA_REPAIR-0.420
- MYC_TARGETS_V1-0.360
- MYC_TARGETS_V2-0.340
- OXIDATIVE_PHOSPHORYLATION-0.330
- E2F_TARGETS-0.320
- ADIPOGENESIS-0.160
- G2M_CHECKPOINT-0.130
- HEDGEHOG_SIGNALING-0.130
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.050
- PI3K_AKT_MTOR_SIGNALING-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 9f621704-2ece-4b25-be28-5fe14f71048d | — | — | 0.917 |
| 2 | ERR2278883 | — | — | 0.916 |
| 3 | MDT-AP-3277 | Med | Medulloblastoma | 0.912 |
| 4 | MDT-AP-2651 | Med | Medulloblastoma | 0.900 |
| 5 | TCGA-CN-5370-01A-01R-2016-07 | — | — | 0.898 |
| 6 | TCGA-DK-A1AF-01A-11R-A13Y-07 | — | — | 0.897 |
| 7 | MDT-AP-2869 | Med | Medulloblastoma | 0.891 |
| 8 | SRR1441701 | GTEX | — | 0.889 |
| 9 | MDT-AP-2111 | Med | Medulloblastoma | 0.889 |
| 10 | BS_AP0SZ364 | low-grade glioma | — | 0.888 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.530 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.520 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.510 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.510 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.500 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.470 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.420 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.420 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| APOPTOSIS | 0.330 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| COMPLEMENT | 0.320 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.220 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |